As President Donald Trump has persistently discussed the malaria drug hydroxychloroquine, critics have wondered about his motivation, given the drug’s far-from-certain performance on the global stage as a treatment for coronavirus, and the Food and Drug Administration’s refusal so far to approve it as a treatment for COVID-19.
The New York Times says Trump has a “small personal stake” in Sanofi, the French drug manufacturer that produces the drug.
The report doesn’t say how small, but it notes that his three family trusts have investments in a Dodge & Cox mutual fund whose largest holding is Sanofi. A fund that matches this description is the Dodge & Cox International Stock Fund US:DODFX, which at last check was 3.3% invested in Sanofi.